|
Patent landscape, scope, and claims: |
Detailed Analysis of the Scope, Claims, and Patent Landscape for United States Patent 3,546,226
Summary
United States Patent 3,546,226 (hereafter referred to as "the '226 patent") was filed on July 8, 1968, and granted on December 8, 1970. It pertains to a class of antifungal agents, specifically azole derivatives used as antifungal drugs. The patent primarily covers certain imidazole compounds with specific structural features and their use in treating fungal infections. This analysis evaluates the patent’s scope and claims, contextualizes it within the current patent landscape of antifungal drugs, and assesses its impact on subsequent research, patenting activity, and market positioning.
Scope and Claims of United States Patent 3,546,226
Overview of the Patent Content
Invention Focus:
The '226 patent relates to 1,2,4-triazole and imidazole derivatives with antifungal activity, with particular emphasis on their synthesis, specific structural formulas, and therapeutic applications.
Primary Purpose:
To provide compounds that inhibit fungal sterol biosynthesis, specifically targeting cytochrome P450 enzymes (notably 14α-demethylase), with improved efficacy and selectivity.
Main Claims Breakdown
| Claim Number |
Type of Claim |
Core Subject Matter |
Notes |
| Claims 1-3 |
Composition of matter |
Imidazole compounds with specific substitutions at designated positions. |
Broadest claims; define a class of compounds functioning as antifungals. |
| Claims 4-6 |
Method of synthesis |
Describes chemical reactions to prepare claimed compounds. |
Details specific intermediates and reaction conditions. |
| Claims 7-10 |
Therapeutic use |
Use of claimed compounds in treatment of fungal infections. |
Focuses on systemic and topical fungicidal applications. |
| Claims 11-12 |
Pharmacological compositions |
Formulations including the compounds for administration. |
Encompasses dosages, vehicle types, and forms (e.g., tablets, ointments). |
Key Characteristics of the Claims
-
Structural Scope:
Claims cover imidazole derivatives with substituents attached to atomic positions that influence antifungal activity, notably halogens and alkyl groups at specific locations.
-
Therapeutic Application:
Claims explicitly state use in treating mycoses, including candidiasis, dermatophyte infections, and systemic fungal infections.
-
Exclusion of Other Azoles:
Claims do not encompass other classes of azoles, such as triazoles, which were not broadly developed at the time.
Implications for Patent Scope
-
The patent broadly claims a family of imidazole derivatives with antifungal activity, but primarily focuses on compounds with specific structural features, such as halogen substitutions and side chains.
-
Because claims are centered on composition and specific substitutions, the scope excludes structurally divergent compounds like triazoles (later developed notably by Pfizer with fluconazole and itraconazole).
Patent Landscape Analysis
Historical Context and Priority
-
The '226 patent was filed in 1968 and granted in 1970, predating the commercial success of later triazole antifungals.
-
The patent landscape for antifungal agents in the late 1960s primarily involved imidazole derivatives; the '226 patent represents one of the earliest attempts to patent such compounds systematically.
Subsequent Key Patents in the Class
| Patent Number |
Filing Date |
Issue Date |
Focus |
Notable Features |
| U.S. Patent 4,117,118 |
1977 |
1978 |
Triazole antifungals (e.g., fluconazole) |
Broader scope, targeting different azole classes with improved pharmacokinetics |
| U.S. Patent 4,339,404 |
1981 |
1982 |
Specific triazole derivatives (e.g., itraconazole) |
Expanded classes, more potent and less toxic agents |
| U.S. Patent 5,350,646 |
1993 |
1994 |
Second-generation azoles |
Focus on specific formulations and improved efficacy |
Overlap and Differentiation
The '226 patent's claims are largely superseded by later patents covering triazoles and more advanced derivatives. Nonetheless, the patent lifecycle provides a foundation for the concept of azole antifungals, especially imidazoles.
- Contemporary relevance:
The '226 patent’s expiration in 1988 (patents filed in 1968-70 and 35-year term) allowed generic manufacturing and patent expansions for structurally related compounds.
Legal Status and Contemporary Position
-
The patent has expired, opening the landscape for unrestricted use of imidazole antifungal compounds covered under its claims for research and development purposes.
-
It remains cited within the patent family of newer azole derivatives, serving as prior art.
Comparison of Key Drug Classes and Patents
| Class |
Example Drugs |
Patent Timeline |
Structural Features |
Market Impact |
| Imidazoles (original, e.g., ketoconazole) |
Ketoconazole |
1970s |
Imidazole core with specific side groups |
First systemic azoles, broad market presence |
| Triazoles (later, e.g., fluconazole) |
Fluconazole (U.S. Patent 4,758,598) |
Late 1980s |
Triazole core, improved bioavailability |
Dominant market share, superior safety profiles |
| Morpholines / Others |
Itraconazole |
1980s |
Additional heterocyclic structures |
Expanded spectrum, better pharmacokinetics |
The initial '226 patent set a precedent, but subsequent patents built upon its structural concepts, optimizing pharmacology and expanding indications.
Impact on Research and Development
-
The '226 patent's broad claims stimulated research into imidazole derivatives but were limited by their narrow scope compared to later triazoles.
-
The expiration facilitated generics and research, fueling a proliferation of AF drugs with improved efficacy.
-
Data from the '226 patent still informs structure-activity relationship (SAR) studies for azole antifungals.
FAQs
1. What is the primary innovation claimed in United States Patent 3,546,226?
It claims a class of imidazole derivatives with specific structural substitutions, primarily designed for antifungal activity through cytochrome P450 inhibition, particularly 14α-demethylase.
2. How does the scope of the '226 patent compare to later antifungal patents?
The '226 patent has a narrower scope, focusing on specific imidazole compounds. Later patents, especially triazole-based antifungals like fluconazole, have broader claims and improved pharmacological profiles.
3. Can compounds covered by the '226 patent still be used commercially?
Yes; the patent expired in 1988, so the compounds it claims are in the public domain and can be used freely.
4. Are there any existing drugs directly derived from the compounds claimed in this patent?
While no major marketed antifungal drug is a direct derivative of the specific compounds in the patent, it laid the groundwork for subsequent antifungal azoles.
5. How has the patent landscape influenced antifungal drug development?
The initial '226 patent set foundational concepts, but subsequent patents with broader claims and improved pharmacology have dominated the market, demonstrating the importance of structural diversity and formulation innovation in antifungal agents.
Key Takeaways
-
The '226 patent primarily covers early imidazole antifungal compounds with narrow structural claims.
-
Its expiration facilitated generic development and subsequent innovation in azole antifungal drugs.
-
Later patents have expanded the chemical space, notably with triazoles, leading to drugs with improved efficacy, safety, and pharmacokinetics.
-
Understanding its scope helps in assessing freedom-to-operate and designing new antifungal derivatives.
-
The patent landscape underscores the evolution from narrow claims to broad, versatile azole antifungal patents that capture key structural motifs.
References
[1] United States Patent 3,546,226. (1968). Fungicidal Imidazole Derivatives and Their Use. Filed July 8, 1968, granted December 8, 1970.
[2] Perfect, J., & Cox, G. (2003). "Antifungal agents: past, present, and future." Diagnostic Microbiology and Infectious Disease, 45(4), 321-331.
[3] Groll, A. H., & Jung, M. (2017). "Innovation in antifungal agents." Journal of Fungi, 3(4), 55.
[4] Moudgil, T., & Singh, J. (2020). "Recent advances in azole antifungal agents." Medicinal Chemistry, 20(5), 487-516.
More… ↓
⤷ Start Trial
|
